ArticleThe New England journal of medicine2021
Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.
Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis.PloS one · 2022Pooled it
- The Shifting Paradigm of Monoclonal Antibodies in COVID-19 Management: From Early Triumphs to Viral Resistance and Future Perspectives.Antibodies (Basel, Switzerland) · 2026Review
- Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination.Journal of clinical virology plus · 2023Article
- The OM-85 bacterial lysate: a new tool against SARS-CoV-2?Multidisciplinary respiratory medicine · 2023Article
- Avidity in antibody effector functions and biotherapeutic drug design.Nature reviews. Drug discovery · 2022Review
- Review
- Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.The Lancet. Respiratory medicine · 2022Review
- A database of anti-coronavirus peptides.Scientific data · 2022Article
- Effective Interferon Lambda Treatment Regimen To Control Lethal MERS-CoV Infection in Mice.Journal of virology · 2022Article
- Structural basis of nanobodies neutralizing SARS-CoV-2 variants.Structure (London, England : 1993) · 2022Article
- Therapeutic strategies to fight COVID-19: Which is the status artis?British journal of pharmacology · 2022Review
- The role of antigen-presenting cells in the pathogenesis of COVID-19.Pathology, research and practice · 2022Review
- Article
- Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease.bioRxiv : the preprint server for biology · 2022Article
- SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.Kidney360 · 2022Article
- Development and Validation of the RCOS Prognostic Index: A Bedside Multivariable Logistic Regression Model to Predict Hypoxaemia or Death in Patients with SARS-CoV-2 Infection.Interdisciplinary perspectives on infectious diseases · 2022Article
- Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?Frontiers in immunology · 2022Review
- Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2.Frontiers in immunology · 2022Review
- Medical countermeasures against henipaviruses: a review and public health perspective.The Lancet. Infectious diseases · 2022Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.